Matthew Zirui Tay

Suggest Changes
Learn More
The use of rituximab has been associated with increased risk of hepatitis B virus (HBV) reactivation in patients who are hepatitis B surface antigen (HBsAg) negative and antihepatitis B core antibody(More)
  • 1